SCHEMBL5570071

SCHEMBL5570071

N#CC(c1ccc(Cl)cc1)c1c(Br)cc(N)cc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NR1I2 O75469 1/20 0.40
GAA P10253 4/20 0.38
MAPT P10636 4/20 0.36
HTT P42858 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C19 P33261 2/20 0.36
POLB P06746 1/20 0.36
CYP2C9 P11712 1/20 0.36
ATM Q13315 1/20 0.36
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ADRB2 P07550 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8145600 0.85 MEN1 (0.48) ALDH1A1L3MBTL1MEN1KMT2ANR1I2
SCHEMBL10420605 0.81 ALDH1A1 (0.43) ALDH1A1L3MBTL1MEN1KMT2ANR1I2
SCHEMBL10420876 0.78 ALDH1A1 (0.41) ALDH1A1L3MBTL1MEN1KMT2ANR1I2
SCHEMBL5565988 0.78 MEN1 (0.39) ALDH1A1L3MBTL1MEN1KMT2ANR1I2
SCHEMBL10436237 0.77 ALDH1A1 (0.51) ALDH1A1L3MBTL1MEN1KMT2ANR1I2
SCHEMBL7825067 0.74 ALDH1A1 (0.60) ALDH1A1L3MBTL1MEN1KMT2ANR1I2
SCHEMBL10672256 0.72 ALDH1A1 (0.46) ALDH1A1L3MBTL1MEN1KMT2ANR1I2
SCHEMBL7843623 0.71 MEN1 (0.45) ALDH1A1L3MBTL1MEN1KMT2ANR1I2
SCHEMBL4799423 0.71 ALDH1A1 (0.46) ALDH1A1L3MBTL1MEN1KMT2ANR1I2
SCHEMBL7838595 0.70 CYP3A4 (0.45) ALDH1A1L3MBTL1MEN1KMT2ANR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1000040-B1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2007-06-13 EP disclosed
US-6951857-B2 Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma FREYNE EDDY JEAN EDGARD 2005-10-04 US disclosed
US-20050090495-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs LACRAMPE JEAN FERNAND ARMAND (FR) 2005-04-28 US disclosed
US-6867207-B2 IL-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-03-15 US disclosed
US-20040167333-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs LACRAMPE JEAN FERNAND ARMAND (FR) 2004-08-26 US disclosed
US-6743792-B2 ANTIINFLAMMATORY AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2004-06-01 US disclosed
US-20030220331-A1 Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma FREYNE EDDY JEAN EDGARD (BE) 2003-11-27 US disclosed
US-20020072603-A1 Novel IL-5 inhibiting 6-azauracil derivatives LACRAMPE JEAN FERNAND ARMAND (FR) 2002-06-13 US disclosed
US-20020042416-A1 Antiinflammatory agents FREYNE EDDY JEAN EDGARD (BE) 2002-04-11 US disclosed
EP-1003729-A1 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2000-05-31 EP disclosed
EP-1000040-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-05-17 EP disclosed
WO-1999002505-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1999-01-21 WO disclosed
WO-1999002504-A1 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 1999-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167333-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs IL6ST, CXCR5, ALOX5 ALDH1A1 1219/4885L3MBTL1 3677/4885MEN1 4239/4885
US-20020042416-A1 Antiinflammatory agents CCR1, CCR6, FPR1 ALDH1A1 957/4885L3MBTL1 4078/4885MEN1 4743/4885
US-20050090495-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs CXCR5, HCAR3, IL6ST ALDH1A1 1331/4885L3MBTL1 2350/4885MEN1 3111/4885
US-20030220331-A1 Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma IL6, CCR1, CCR6 ALDH1A1 918/4885L3MBTL1 4152/4885MEN1 4804/4885
US-20020072603-A1 Novel IL-5 inhibiting 6-azauracil derivatives IL6ST, ALOX5, IL5 ALDH1A1 848/4885L3MBTL1 3378/4885MEN1 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.